We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So talking multi billions of kits to be sold and AVCT holds all commercial rights to future products also.
The WHOLE WORLD will be back to work with such a test as this. Sold to industries and for personal use worldwide.
Renders all other testing not obsolete but certainly inferior for speed and efficiency.
No brainer here's why:
The Wetherby-based firm will collaborate with life sciences firm Cytiva to create a test that can diagnose the infection within minutes using a respiratory sample such as saliva.
"Importantly the test will indicate if a person has the virus now, whether they are showing symptoms or not, and will do so in minutes, in-situ with no need for laboratory equipment.
Existing tests are not suitable for screening large numbers of people for the infection as they are laboratory based and it can take up to several days to get the results.
Looking good!
https://twitter.com/gregwrightyp/status/1247806112406986754?s=21
Why would they enter this agreement if they felt it was too late, game changer here - to the person who mentioned it thanks for the tip.
All money and resources are being ploughed into this cause right now and AVCT are in with the top tier.
True that
You realise summer is in the next 2 months right lad?
Corona viruses are the new terrorists they are here to stay.
AVCT CO WILL OWN INTELLECTUAL PROPERTY RELATING TO COVID-19
WORLDWIDE DISTRIBUTION
Sounds brilliant - only concern is are they too far behind the competition as targeting the summer to produce. ( If your talking within next month - Brilliant but when in Summer plus all regulatory approvals will need to be obtained )
Might be worth a very small dabble at this point.
Never too late to join here this just the start after that news
The big one. AVACTA GROUP PLC - CO WILL OWN INTELLECTUAL PROPERTY RELATING TO COVID-19 AFFIMER-REAGENTS AND WILL RETAIN ALL COMMERCIAL RIGHTS TO FUTURE PRODUCTS
AVACTA GROUP PLC SAYS ENTERED INTO A COLLABORATION WITH CYTIVA, FORMERLY KNOWN AS GE HEALTHCARE LIFE SCIENCES
AVACTA GROUP PLC SAYS PARTNERSHIP TO DEVELOP AND MANUFACTURE A RAPID TEST FOR COVID-19 CORONAVIRUS INFECTION FOR POPULATION SCREENING
Media started. Reuter’s
BRIEF-Avacta Entered Into Deal With Cytiva To Develop And Manufacture Rapid Test For Covid-19 Coronavirus
https://uk.mobile.reuters.com/article/amp/idUKFWN2BV1LX?__twitter_impression=true
Caught this news late but luckily so has the market. Sustained interest and rise from these levels. Critical for the world and now in with a huge major.
This will also gain WHO Emergency use status like NCYT and ALREADY has a collaboration with a $96 BILLION NYSE listed company for immediate Worldwide distribution like NCYT.
This is my chance to get in on the next NCYT at the beginning
Agree with this POV
Reason I invested here is you have a firm base of operations from the current technology, worth 20p
That part of the business is valued circa £35m
Now you have a partnership, with a huge major - developing not only a test kit (and an antigen one which is in more demand) but potentially a market leading test kit, which major advantages over the rest of the market
This side of the business, at current SP upside, is worth around £20m
So basically you are getting a potentially lucrative test-kit diagnostics business, for 20m
What's the share price of #NCYT again?
https:// t.me/joinchat /N1FTDBzhKek8_utivRL_CQ
Remove spaces
AVCT group open
**********************N1FTDBzhKek8_utivRL_CQ
Rapid results in minutes for the masses. No lab required and for home use
https://avacta.wistia.com/medias/rijiipm9xt
"I am delighted that we have established this collaboration with Cytiva to develop, manufacture and commercialise a rapid test for COVID-19 infection. Importantly the test will indicate if a person has the virus now, whether they are showing symptoms or not, and will do so in MINUTES, in-situ with no need for laboratory equipment.
Unfortunately, many millions of people around the world will ultimately become infected and it is likely to be an annual occurrence.